Director at Immunic (IMUX) gets options at $10.12 a share
Immunic (IMUX) granted director Robert Thorvald Nagel 25,370 stock options at $10.12 per share. The options vest monthly over one year and expire in 2036. The economic benefits will be transferred to BVF Partners L.P.
How this was made
The 30-second read
Why it matters
The grant is a routine compensation event with negligible market impact.
Market read
Low relevance; primarily of interest to existing shareholders and compliance monitors.
What to watch
Potential future insider buying pressure if the director later acquires shares beyond the option grant.
Background
Immunic filed a Form 4 reporting a director's stock option grant.
Ticker impact
Director Robert Thorvald Nagel was granted 25,370 stock options at $10.12 per share, vesting monthly over one year.
minimal effect on share price
The grant size is tiny relative to float and the exercise price is near current market levels, so traders are unlikely to act.
Market effects
None; the grant does not affect the biotech sector broadly.
No regional impact expected.
Limited to Immunic shareholders.
Counterpoint
If the director plans to exercise and sell, a slight upside could emerge if the stock rallies above $10.12.
Key entities
- DirectorRobert Thorvald Nagel
Recipient of the option grant.
- BeneficiaryBVF Partners L.P.
Entity to receive any economic benefit from the options.
